Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 528

The DOI matches its Crossref record; 91 of the 91 references it cites were found in a registry or an index.

Antagonist Antibodies to PD-1 and B7-H1 (PD-L1) in the Treatment of Advanced Human Cancer—Response

Open access
Sznol, Mario, Chen, Lieping·2013·Clinical Cancer Research

Abstract

We wish to thank Radvanyi and colleagues for their excellent letter that documents the strong rationale to combine PD-1 signaling blockade with adoptively transferred antigen-specific T cells or ex vivo expanded tumor-infiltrating lymphocytes (TIL). Our review was not meant to be comprehensive and space limitations precluded mention of all potentially relevant combinations with antagonists of PD-1 signaling. In fact, the first experimental data showing the application of anti-PD-L1 antibody for the treatment of cancer were generated in an adoptive T-cell transfer model (1). Very recent data from the phase I trial of nivolumab and ipilimumab in metastatic melanoma provided evidence for the hypothesis that combining PD-1 signaling blockade with other immunotherapy agents or approaches will improve treatment outcome (2). One of our patients on the latter trial, whose disease progressed on the combination of nivolumab and ipilimumab, subsequently responded to TIL therapy administered at another center. Although only an anecdote, it suggests a relevant role for cell therapies even in this era of other highly active immune-modulating agents (2). We look forward to the clinical data from trials combining adoptive cell therapy with anti-PD1 or anti-PD-L1.See the original Letter to the Editor, p. 5541M. Sznol is a consultant/advisory board member of Bristol-Myers Squibb, Genesis Biopharma, and MedImmune. No potential conflicts of interest were disclosed by the other author.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-13-2234

Cites

91 of 91 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 91 references

Cited by

See all 528

Metadata

Authors
Sznol, M., & Chen, L.
Venue
Clinical Cancer Research
Published
2013-10-01
Volume
19
Issue
19
Pages
5542-5542
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W2156383220
Cited by
528
References
91
FWCI
33.52
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Antagonist Antibodies to PD-1 and B7-H1 (PD-L1) in the Treatment of Advanced Human Cancer—Response. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-13-2234
The paper
Sznol, M., & Chen, L. (2013). Antagonist Antibodies to PD-1 and B7-H1 (PD-L1) in the Treatment of Advanced Human Cancer—Response. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-13-2234

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.